Literature DB >> 15808810

The renin-angiotensin-aldosterone system, glucose metabolism and diabetes.

Gilberta Giacchetti1, Leonardo A Sechi, Silvia Rilli, Robert M Carey.   

Abstract

In diabetes mellitus (DM), the circulating renin-angiotensin system (RAS) is suppressed, but the renal tissue RAS is activated. Hyperglycemia increases tissue angiotensin II (Ang II), which induces oxidative stress, endothelial damage and disease pathology including vasoconstriction, thrombosis, inflammation and vascular remodeling. In early DM, the type 1 Ang II (AT(1)) receptor is upregulated but the type 2 Ang II (AT(2)) receptor is downregulated. This imbalance can predispose the individual to tissue damage. Hyperglycemia also increases the production of aldosterone, which has an unknown contribution to tissue damage. The insulin resistance state is associated with upregulation of the AT(1) receptor and an increase in oxygen free radicals in endothelial tissue caused by activation of NAD(P)H oxidase. Treatment with an AT(1) receptor blocker normalizes oxidase activity and improves endothelial function. An understanding of the tissue renin-angiotensin-aldosterone system, which is a crucial factor in the progression of tissue damage in DM, is imperative for protection against tissue damage in this chronic disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808810     DOI: 10.1016/j.tem.2005.02.003

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  59 in total

Review 1.  Intracardiac intracellular angiotensin system in diabetes.

Authors:  Rajesh Kumar; Qian Chen Yong; Candice M Thomas; Kenneth M Baker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

2.  [Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice].

Authors:  Xian-Lang Ye; Wei-Chang Huang; Yan-Tao Zheng; Ying Liang; Wang-Qiu Gong; Chong-Miao Yang; Bin Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

Review 3.  New molecular insights in diabetic nephropathy.

Authors:  Ionel Alexandru Checheriţă; Gina Manda; Mihai Eugen Hinescu; Ileana Peride; Andrei Niculae; Ştefana Bîlha; Angelica Grămăticu; Luminiţa Voroneanu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

4.  Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis.

Authors:  Vaibhav B Patel; Sreedhar Bodiga; Ratnadeep Basu; Subhash K Das; Wang Wang; Zuocheng Wang; Jennifer Lo; Maria B Grant; JiuChang Zhong; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circ Res       Date:  2012-04-03       Impact factor: 17.367

5.  Renoprotective effect of lansoprazole in streptozotocin-induced diabetic nephropathy in wistar rats.

Authors:  Rupinder Kaur; Rupinder Kaur Sodhi; Neha Aggarwal; Jaspreet Kaur; Upendra K Jain
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-10-16       Impact factor: 3.000

Review 6.  Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.

Authors:  Terry K W Ma; Kevin K H Kam; Bryan P Yan; Yat-Yin Lam
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 7.  Application of direct renin inhibition to chronic kidney disease.

Authors:  Christian W Mende
Journal:  Cardiovasc Drugs Ther       Date:  2010-04       Impact factor: 3.727

Review 8.  The effect of RAAS blockade on the progression of diabetic nephropathy.

Authors:  Sara S Roscioni; Hiddo J Lambers Heerspink; Dick de Zeeuw
Journal:  Nat Rev Nephrol       Date:  2013-12-03       Impact factor: 28.314

9.  Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.

Authors:  Paola Failli; Chiara Alfarano; Sergio Franchi-Micheli; Edoardo Mannucci; Elisabetta Cerbai; Alessandro Mugelli; Laura Raimondi
Journal:  Cardiovasc Diabetol       Date:  2009-06-22       Impact factor: 9.951

10.  The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.

Authors:  Carolyn M Ecelbarger; Arjun Rash; Rajesh K Sinha; Swasti Tiwari
Journal:  Mediators Inflamm       Date:  2010-05-17       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.